These values, in addition to CI values lower than 1, indicate that MEN1611 and gefitinib are synergistic in the RA1, RB1, and RA2 EGFR-TKI-resistant NSCLC cell lines (Table 3; Figure S2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.